<DOC>
	<DOCNO>NCT02045563</DOCNO>
	<brief_summary>- Our research hypothesis show certain number genetic polymorphism protein involve glucose , lipid adipocyte metabolism factor favour development steatosis patient Type 2 diabetes . - We also wish evaluate thoroughly lipid anomaly associate presence steatosis , notably regard monocyte expression LDL receptor . We hypothesize hepatic steatosis accompany activation transcription factor involve lipogenesis , notably SREBP factor . The activation factor could cause increase expression LDL receptor , lead increase LDL catabolism . - Chronological description study During outpatient consultation endocrinology department , diabetic patient , program undergo examination ass diabetes invite participate study . Once write informed consent provide clinical data record , patient type 1 type 2 diabetes standard biological examination , systematically do patient ( Fasting glycemia , HBA1c , aspartate aminotransferase , alanine amino transferase , Gammaglutamyl-transferases , PAL , bilirubin , blood protein , albuminemia , Total Cholesterol total , HDL cholesterol , triglyceride , Sedimentation Rate , C-reactive protein , fibrinogen ) . As well systematic biological test , 3 additional tube take screen genetic polymorphism 3 protein ( Microsomal Transfer Protein , Adiponectin receptor - 1 , Apolipoprotein A - II ) . IN addition , magnetic resonance image magnetic resonance spectroscopy do look presence liver steatosis measure carotid intima-media thickness .</brief_summary>
	<brief_title>Genetic Polymorphisms , Steatosis Diabetes</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion Type2 diabetic : Type 2 diabetes HbA1C &gt; 6.5 % 27 &lt; BMI &lt; 55 Inclusion criterion Type1 diabetic : Type 1 diabetes BMI &lt; 55 Diagnosis type1 diabetes base clinical history patient and/or presence antiglutamate decarboxylase auto antibody and/or plasma level C peptide 0,5 ng/l . Inclusion criterion healthy volunteer : Non diabetic Alcohol consumption &lt; 2 glass per day Without hyperglycemic treatment ( corticoid , ... ) Without liver disease ( cirrhosis , hepatitis , ... ) Pacemaker Daily alcohol consumption 4 glass per day Patients treat Glitazones 3 month precede inclusion Presence implant Claustrophobia Patient &lt; 18 year Patient guardianship intellectually independent Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>